Publication

Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-years Prospective Cohort Study

Sotomayor, C. G., Te Velde-Keyzer, C. A., Diepstra, A., van Londen, M., Pol, R. A., Post, A., Gans, R. O. B., Nolte, I. M., Slart, R. H. J. A., de Borst, M. H., Berger, S. P., Rodrigo, R., Navis, G. J., de Boer, R. A. & Bakker, S. J. L., 25-Jun-2020, In : Transplantation. 38 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Sotomayor, C. G., Te Velde-Keyzer, C. A., Diepstra, A., van Londen, M., Pol, R. A., Post, A., Gans, R. O. B., Nolte, I. M., Slart, R. H. J. A., de Borst, M. H., Berger, S. P., Rodrigo, R., Navis, G. J., de Boer, R. A., & Bakker, S. J. L. (2020). Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-years Prospective Cohort Study. Transplantation. https://doi.org/10.1097/TP.0000000000003359

Author

Sotomayor, Camilo G ; Te Velde-Keyzer, Charlotte A ; Diepstra, Arjan ; van Londen, Marco ; Pol, Robert A ; Post, Adrian ; Gans, Rijk O B ; Nolte, Ilja M ; Slart, Riemer H J A ; de Borst, Martin H ; Berger, Stefan P ; Rodrigo, Ramón ; Navis, Gerjan J ; de Boer, Rudolf A ; Bakker, Stephan J L. / Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients : A 10-years Prospective Cohort Study. In: Transplantation. 2020.

Harvard

Sotomayor, CG, Te Velde-Keyzer, CA, Diepstra, A, van Londen, M, Pol, RA, Post, A, Gans, ROB, Nolte, IM, Slart, RHJA, de Borst, MH, Berger, SP, Rodrigo, R, Navis, GJ, de Boer, RA & Bakker, SJL 2020, 'Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-years Prospective Cohort Study', Transplantation. https://doi.org/10.1097/TP.0000000000003359

Standard

Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients : A 10-years Prospective Cohort Study. / Sotomayor, Camilo G; Te Velde-Keyzer, Charlotte A; Diepstra, Arjan; van Londen, Marco; Pol, Robert A; Post, Adrian; Gans, Rijk O B; Nolte, Ilja M; Slart, Riemer H J A; de Borst, Martin H; Berger, Stefan P; Rodrigo, Ramón; Navis, Gerjan J; de Boer, Rudolf A; Bakker, Stephan J L.

In: Transplantation, 25.06.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Sotomayor CG, Te Velde-Keyzer CA, Diepstra A, van Londen M, Pol RA, Post A et al. Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-years Prospective Cohort Study. Transplantation. 2020 Jun 25. https://doi.org/10.1097/TP.0000000000003359


BibTeX

@article{ea53c10774244feea56fb38a82bb32f4,
title = "Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-years Prospective Cohort Study",
abstract = "BACKGROUND: Galectin-3 may play a causal role in kidney inflammation and fibrosis, which may also be involved in the development of kidney graft failure. With novel galectin-3 targeted pharmacological therapies increasingly coming available, we aimed to investigate whether galectin-3 is associated with risk of late graft failure in kidney transplant recipients (KTR).METHODS: We studied adult KTR who participated in TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study, recruited in a university setting (2001-2003). Follow-up was performed for a median of 9.5 (IQR, 6.2-10.2) years. Overall and stratified (Pinteraction<0.05) multivariable-adjusted Cox proportional-hazards regression analyses were performed to study the association of galectin-3 with graft failure (restart of dialysis or retransplantation).RESULTS: Among 561 KTR (age 52 ± 12 years; 54% males), baseline median galectin-3 was 21.1 (IQR, 17.0-27.2) ng/mL. During follow-up, 72 KTR developed graft failure (13, 18, and 44 events over increasing tertiles of galectin-3). Independent of adjustment for donor, recipient, and transplant characteristics, galectin-3 associated with increased risk of graft failure (HR per 1-SD change, 2.12; 95%CI 1.63-2.75; P<0.001), particularly among KTR with systolic blood pressure ≥140mmHg (HR=2.29; 95%CI=1.80-2.92; P<0.001; Pinteraction=0.01) or smoking history (HR=2.56; 95%CI=1.95-3.37; P<0.001; Pinteraction=0.03). Similarly, patients in the highest tertile of galectin-3 were consistently at increased risk of graft failure.CONCLUSIONS: Serum galectin-3 levels are elevated in KTR, and independently associated with increased risk of late graft failure. Whether galectin-3-targeted therapies may represent novel opportunities to decrease the long-standing high burden of late graft failure in stable KTR warrants further studies.",
author = "Sotomayor, {Camilo G} and {Te Velde-Keyzer}, {Charlotte A} and Arjan Diepstra and {van Londen}, Marco and Pol, {Robert A} and Adrian Post and Gans, {Rijk O B} and Nolte, {Ilja M} and Slart, {Riemer H J A} and {de Borst}, {Martin H} and Berger, {Stefan P} and Ram{\'o}n Rodrigo and Navis, {Gerjan J} and {de Boer}, {Rudolf A} and Bakker, {Stephan J L}",
year = "2020",
month = jun,
day = "25",
doi = "10.1097/TP.0000000000003359",
language = "English",
journal = "Transplantation",
issn = "0041-1337",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",

}

RIS

TY - JOUR

T1 - Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients

T2 - A 10-years Prospective Cohort Study

AU - Sotomayor, Camilo G

AU - Te Velde-Keyzer, Charlotte A

AU - Diepstra, Arjan

AU - van Londen, Marco

AU - Pol, Robert A

AU - Post, Adrian

AU - Gans, Rijk O B

AU - Nolte, Ilja M

AU - Slart, Riemer H J A

AU - de Borst, Martin H

AU - Berger, Stefan P

AU - Rodrigo, Ramón

AU - Navis, Gerjan J

AU - de Boer, Rudolf A

AU - Bakker, Stephan J L

PY - 2020/6/25

Y1 - 2020/6/25

N2 - BACKGROUND: Galectin-3 may play a causal role in kidney inflammation and fibrosis, which may also be involved in the development of kidney graft failure. With novel galectin-3 targeted pharmacological therapies increasingly coming available, we aimed to investigate whether galectin-3 is associated with risk of late graft failure in kidney transplant recipients (KTR).METHODS: We studied adult KTR who participated in TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study, recruited in a university setting (2001-2003). Follow-up was performed for a median of 9.5 (IQR, 6.2-10.2) years. Overall and stratified (Pinteraction<0.05) multivariable-adjusted Cox proportional-hazards regression analyses were performed to study the association of galectin-3 with graft failure (restart of dialysis or retransplantation).RESULTS: Among 561 KTR (age 52 ± 12 years; 54% males), baseline median galectin-3 was 21.1 (IQR, 17.0-27.2) ng/mL. During follow-up, 72 KTR developed graft failure (13, 18, and 44 events over increasing tertiles of galectin-3). Independent of adjustment for donor, recipient, and transplant characteristics, galectin-3 associated with increased risk of graft failure (HR per 1-SD change, 2.12; 95%CI 1.63-2.75; P<0.001), particularly among KTR with systolic blood pressure ≥140mmHg (HR=2.29; 95%CI=1.80-2.92; P<0.001; Pinteraction=0.01) or smoking history (HR=2.56; 95%CI=1.95-3.37; P<0.001; Pinteraction=0.03). Similarly, patients in the highest tertile of galectin-3 were consistently at increased risk of graft failure.CONCLUSIONS: Serum galectin-3 levels are elevated in KTR, and independently associated with increased risk of late graft failure. Whether galectin-3-targeted therapies may represent novel opportunities to decrease the long-standing high burden of late graft failure in stable KTR warrants further studies.

AB - BACKGROUND: Galectin-3 may play a causal role in kidney inflammation and fibrosis, which may also be involved in the development of kidney graft failure. With novel galectin-3 targeted pharmacological therapies increasingly coming available, we aimed to investigate whether galectin-3 is associated with risk of late graft failure in kidney transplant recipients (KTR).METHODS: We studied adult KTR who participated in TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study, recruited in a university setting (2001-2003). Follow-up was performed for a median of 9.5 (IQR, 6.2-10.2) years. Overall and stratified (Pinteraction<0.05) multivariable-adjusted Cox proportional-hazards regression analyses were performed to study the association of galectin-3 with graft failure (restart of dialysis or retransplantation).RESULTS: Among 561 KTR (age 52 ± 12 years; 54% males), baseline median galectin-3 was 21.1 (IQR, 17.0-27.2) ng/mL. During follow-up, 72 KTR developed graft failure (13, 18, and 44 events over increasing tertiles of galectin-3). Independent of adjustment for donor, recipient, and transplant characteristics, galectin-3 associated with increased risk of graft failure (HR per 1-SD change, 2.12; 95%CI 1.63-2.75; P<0.001), particularly among KTR with systolic blood pressure ≥140mmHg (HR=2.29; 95%CI=1.80-2.92; P<0.001; Pinteraction=0.01) or smoking history (HR=2.56; 95%CI=1.95-3.37; P<0.001; Pinteraction=0.03). Similarly, patients in the highest tertile of galectin-3 were consistently at increased risk of graft failure.CONCLUSIONS: Serum galectin-3 levels are elevated in KTR, and independently associated with increased risk of late graft failure. Whether galectin-3-targeted therapies may represent novel opportunities to decrease the long-standing high burden of late graft failure in stable KTR warrants further studies.

U2 - 10.1097/TP.0000000000003359

DO - 10.1097/TP.0000000000003359

M3 - Article

C2 - 32639409

JO - Transplantation

JF - Transplantation

SN - 0041-1337

ER -

ID: 129243872